FDA 483 - AbbVie Ltd - April 18, 2024
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
AbbVie Ltd in Barceloneta, PR, was cited for significant quality control deficiencies during an FDA inspection from April 10-18, 2024. The firm failed to thoroughly investigate unexplained discrepancies, including microbial contamination in raw materials, cleaning validation samples, and pharmaceutical products like Synthroid tablets. Additionally, the microbiology laboratory lacked adequate controls for tracking microorganisms and establishing trends from environmental monitoring samples.
ID · 5b5d5729-ba72-422f-a406-f7a5a4a090cd